Searchable abstracts of presentations at key conferences in endocrinology

ea0049s19.1 | How to incorporate the new guidelines for thyroid cancer in my clinical practice | ECE2017

Thyroid microcarcinoma: to treat or not to treat?

Vitti Paolo

In the last 20 years, the incidence of thyroid cancer (TC) has more than doubled. Since 50% of the increase is related to papillary microcarcinomas (mPTC, <1 cm), it appears that an increased detection, due to the wide use of neck ultrasound (US), is the major factor driving this dramatic rise. Autoptic and histological studies after thyroidectomy (TX) show that 10 to 30% of adults harbor an undiagnosed mPTC. The disease-specific mortality of patients treated by s...

ea0022s20.1 | The endocrine incidentaloma | ECE2010

The endocrine incidentaloma

Vitti Paolo

Small, non-palpable thyroid nodules, detectable by thyroid ultrasound (US) in 30–50% of the general population, are likely to cause no significant health problem, thus deserving the definition of ‘thyroid incidentalomas’. Although clinically overt thyroid cancer is relatively rare, the most relevant issue for thyroid incidentalomas is the exclusion of malignancy by cytological examination of material obtained by fine needle aspiration (FNA). However, in about 30...

ea0014p376 | (1) | ECE2007

Increase of L-thyroxine requirement during pregnancy

Russo Laura , Tonacchera Massimo , Gianetti Elena , Vitti Paolo , Pinchera Aldo

In pregnant women with a thyroid disease an increased amount of LT4 may be required for the correction of hypothyroidism or treatment of nodular goiter.Aim of this study was to assess the amount of the variations of LT4 requirement in pregnant women with thyroid diseases.To address this issue, we retrospectively evaluated a cohort of 138 women treated with LT4 divided in two groups: 47 euthyroid (E) (affected by nodular goiter (NG)...

ea0014p377 | (1) | ECE2007

Safety of pharmacological treatment of thyroid diseases &br;during pregnancy

Gianetti Elena , Tonacchera Massimo , Russo Laura , Vitti Paolo , Pinchera Aldo

Pregnant women may require treatment of hypo- or hyperthyroidism, L-thyroxine (LT4), propylthiouralcil (PTU) and methimazole (MMI) being the most frequently used drugs. Aim of this study was to verify the consequences of pharmacological treatment during pregnancy. We retrospectively evaluated 379 pregnancies: 124 patients under MMI treatment, 35 of whom still hyperthyroid in spite of treatment (H-MMI) and 89 euthyroid (E-MMI); 52 GD patients under PTU, 20 of whom still hyperth...

ea0056p1028 | Thyroid (non-cancer) | ECE2018

IgM thyroglobulin autoantibodies are detectable in serum of patients with subacute thyroiditis

Brancatella Alessandro , Ricci Debora , Marino Michele , Vitti Paolo , Latrofa Francesco

Context: Subacute thyroiditis (SAT) is an inflammation of the thyroid, likely caused by a viral infection. IgG Autoantibodies (Ab) to the main thyroid antigens, including thyroglobulin (Tg) (TgAb) have been reported in a few patients with SAT and their appearance is usually transient. We investigated whether IgM TgAb can be detected in sera of patients with SAT.Design: Serum samples were collected from 17 patients with SAT, ten with Graves’ disease ...

ea0081p473 | Thyroid | ECE2022

Comparison of serum calcitonin and neck ultrasound sensitivities in identifying medullary thyroid carcinoma

Matrone Antonio , Gambale Carla , Prete Alessandro , Cappagli Virginia , Lorusso Loredana , Bottici Valeria , Vitti Paolo , Elisei Rossella

Background: Serum calcitonin (CT) is a very sensitive test for the diagnosis of medullary thyroid carcinoma (MTC). However, its routine dosage in patients with nodular thyroid disease is not recommended by all scientific societies. In addition, to optimize costs, it is only suggested in the case of suspicious nodules on ultrasound, indeterminate nodules at cytology or nodular goiter before surgery. The aim of the study is to evaluate the serum CT in a series of consecutive MTC...

ea0063p392 | Thyroid 1 | ECE2019

The presence of tall cells, even if

Matrone Antonio , Gambale Carla , Torregrossa Liborio , Valerio Laura , Molinaro Eleonora , Basolo Fulvio , Vitti Paolo , Elisei Rossella

Background: CV-PTC is often indolent with excellent long-term response, while TCV-PTC (≥50% of tall cells) have aggressive features and worse clinical behavior. Less is known about the clinical behavior of CV-PTC with tall cells <50% (TC/CV-PTC) that, so far, is considered as low risk tumor.Aim: To evaluate the histological presentation of CV-PTC, TC/CV-PTC, TCV-PTC and their clinical behavior after 6 years of follow up.M...

ea0063p610 | Diabetes, Obesity and Metabolism 2 | ECE2019

Description of a novel AGPAT2 gene mutation (R159C) responsible for congenital generalized lipoatrophy type 1 (Berardinelli-Seip Syndrome)

Magno Silvia , Ceccarini Giovanni , Pelosini Caterina , Ferrari Federica , Scabia Gaia , Maffei Margherita , Vitti Paolo , Santini Ferruccio

Berardinelli-Seip congenital lipoatrophy type 1 (BSCL1) is a rare autosomal recessive disease caused by mutations in the AGPAT2 gene. This syndrome is characterized by near total absence of adipose tissue since birth, associated with the progressive development of metabolic complications. The AGPAT2 gene encodes for 1-acylglycerol-3phosphate-O-acyltransferase highly expressed in white adipocytes that catalyzes the acylation of lysophosphatidic acid to form phosphatidic acid, a...

ea0063p708 | Pituitary and Neuroendocrinology 2 | ECE2019

Hypophysitis secondary to anti-pd1/pd-l1 blockade: variations in presentation, four distinct cases

Lanzolla Giulia , Viola Nicola , Brancatella Alessandro , Latrofa Francesco , Marcocci Claudio , Vitti Paolo , Lupi Isabella

PD-1/PD-L1 pathway is a key regulator in T-cell activation and tolerance. Nivolumab, pembrolizumab (a PD-1 inhibitors) and atezolizumab (a PD-L1 inhibitor) are monoclonal antibodies approved for treatment of advanced cancers. Autoimmune thyroid diseases are the most common immune-related adverse effects (IrAEs) occurring after anti-PD-1 or anti-PD-L1 therapy, whereas autoimmune hypophysitis is described more frequently in patients treated with anti-CTLA-4. IrAEs can be isolate...

ea0063p765 | Thyroid 2 | ECE2019

Thyroid disfunction during treatment with Nivolumab: nuances in clinical presentation

Brancatella Alessandro , Viola Nicola , Lanzolla Giulia , Vitti Paolo , Marcocci Claudio , Latrofa Francesco , Lupi Isabella

Context: Monoclonal antibodies to Immune Check Point inhibitors (ICPis) are powerful anti-cancer drugs. They trigger the immune system against cancer cells, blocking inhibitory signals of T-Cells. However, ICPi therapy can also stimulate autoimmune reactions, inducing the so-called immune-related adverse events (irAEs). Endocrinopathies are common iRAEs and thyroid disfunction is the most common endocrinopathy during ICP therapy. We report three cases of thyroid disfunction du...